**Novo Nordisk A/S response**

We kindly refer to our webpage in order for you to get the most recent update on our efforts: [Ukraine invasion | Our response (novonordisk.com)](https://www.novonordisk.com/news-and-media/critical-updates.html)

In brief, we are very committed towards patients, employees, and to medicine & supply donations:

**Commitment to patients**

As a pharmaceutical company, it is our responsibility to supply essential medicine to patients with chronic diseases, and we will do all we can to maintain supply in Ukraine and Russia.

With normal supply chains disrupted, we are in dialogue with several international humanitarian organisations to provide relief and have donated medicines and supplies to the Ukrainian Ministry of Health.

**Commitment to employees**

Although our offices in the besieged capital of Kyiv were shuttered on 24 February, we remain in regular contact with our Ukrainian colleagues – all of whom have been reported safe and unharmed at this time.

We have provided emergency funds to all affected employees to help meet the costs of evacuation. Furthermore, we are coordinating support in neighbouring countries for colleagues and/or their families who wish to leave Ukraine.

The Novo Nordisk Foundation has donated 55 million Danish kroner (approx 7.4m Euro) to the efforts, including 5 million Danish kroner (approx 700k Euro) to the UNHCR – the UN’s refugee agency - to provide urgent support and protection to people forced to flee their homes.

**Commitment to medicine supply & donations**

We are doing all we can to maintain the supply of essential medicines to patients living with chronic diseases in Ukraine.

We have donated up to two months' supply of life-saving medicine for diabetes and haemophilia from our current stock in Ukraine to the Ministry of Health.

We are in dialogue with several international humanitarian organisations to assess need for product donations. We are looking into different ways we can positively contribute including through our own supply chain capacity and expertise.

**Patient & HCP hotline**

We have established a hotline for patients and healthcare providers in Ukraine to inform about the availability of our products. We will do our utmost to provide all necessary information.

**Assessing and mitigating risks**

We continue to follow our processes including thorough compliance assessments, including but not limited to close follow-up to secure compliance with sanctions and export control. We have implemented very thorough sanction screening set-up for both individuals, vendors, third parties, and banks. Further, we continue to follow our enhanced processes regarding thorough compliance assessments and due diligences, including human rights.

We have a strong set-up in place with cross-functional Crisis Response Teams, constantly assessing the situation and required measures, based on external and internal sources.